Outlook Therapeutics Inc OTLK Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.44 down $0.00, 0.61% at close Nov 6
Last close · Previous close $0.44
- Market cap
- $52.74MAt the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.77Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.44down $0.00, 0.61%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.44Nov 5
- Volume1.64MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume3.66MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.16 to $2.54; now $0.44
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
OTLK trailed the S&P 500 in all 7 periods.
| Period | OTLK and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | OTLK: down 23.7% S&P 500: down 5.6% | OTLK trailed the S&P 500 by 18.1 percentage points Trailed |
| 3M | OTLK: down 55.1% S&P 500: down 4.1% | OTLK trailed the S&P 500 by 51.0 percentage points Trailed |
| YTD | OTLK: down 72.4% S&P 500: up 8.7% | OTLK trailed the S&P 500 by 81.1 percentage points Trailed |
| 1Y | OTLK: down 63.0% S&P 500: up 10.9% | OTLK trailed the S&P 500 by 73.9 percentage points Trailed |
| Long term | ||
| 3Y | OTLK: down 95.1% S&P 500: up 75.0% −63.5% vs +20.5% a year | OTLK trailed the S&P 500 by 170.1 percentage points Trailed |
| 5Y | OTLK: down 99.0% S&P 500: up 67.8% −59.8% vs +10.9% a year | OTLK trailed the S&P 500 by 166.8 percentage points Trailed |
| 10Y | OTLK: down 99.9% S&P 500: up 313.1% −52.0% vs +15.2% a year | OTLK trailed the S&P 500 by 413.0 percentage points Trailed |
$10,000 invested in OTLK 10 years ago (Nov 4, 2016) would be worth about $7 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
OTLK trailed the S&P 500 in all 7 periods.
| Period | OTLK and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | OTLK: down 23.7% S&P 500: down 5.6% | OTLK trailed the S&P 500 by 18.1 percentage points Trailed |
| 3M | OTLK: down 55.1% S&P 500: down 4.3% | OTLK trailed the S&P 500 by 50.8 percentage points Trailed |
| YTD | OTLK: down 72.4% S&P 500: up 7.8% | OTLK trailed the S&P 500 by 80.2 percentage points Trailed |
| 1Y | OTLK: down 63.0% S&P 500: up 9.7% | OTLK trailed the S&P 500 by 72.7 percentage points Trailed |
| Long term | ||
| 3Y | OTLK: down 95.1% S&P 500: up 68.8% −63.5% vs +19.1% a year | OTLK trailed the S&P 500 by 163.9 percentage points Trailed |
| 5Y | OTLK: down 99.0% S&P 500: up 56.9% −59.8% vs +9.4% a year | OTLK trailed the S&P 500 by 155.9 percentage points Trailed |
| 10Y | OTLK: down 99.9% S&P 500: up 252.6% −52.0% vs +13.4% a year | OTLK trailed the S&P 500 by 352.5 percentage points Trailed |
$10,000 invested in OTLK 10 years ago (Nov 4, 2016) would be worth about $7 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$867.20
Closing high on . Now 99.9% below that record.
Split-adjusted daily closes since Jun 14, 2016.
Stock splits
2
Latest: 1-for-20 on . Share counts adjust after each split.
Both splits
- 1-for-20
- 1-for-8
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$0.77 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- −106.47%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $59.93MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own OTLK DCF in Excel. Value Outlook Therapeutics with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- −$1.16Mdown 177.3%
- Net income
- −$61.12M
- Diluted EPS
- −$0.77
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Sep 30, 2024) | $0.00 | $5.69M | $0.76 |
| Q1 FY25 (Dec 31, 2024) | $0.00 | $17.38M | $0.72 |
| Q2 FY25 (Mar 31, 2025) | $0.00 | −$46.36M | −$1.50 |
| Q3 FY25 (Jun 30, 2025) | $1.51M | −$20.15M | −$0.55 |
| Q4 FY25 (Sep 30, 2025) | −$91.79K | −$13.29M | −$0.19 |
| Q1 FY26 (Dec 31, 2025) | −$1.21M | −$23.06M | −$0.38 |
| Q2 FY26 (Mar 31, 2026) | $127.44K | −$4.45M | −$0.05 |
| Q3 FY26 (Jun 30, 2026) | $8.70K | −$20.32M | −$0.15 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Sep 30, 2021) | $0.00 | −$53.16M | Paused See the note under the price. |
| FY22 (Sep 30, 2022) | $0.00 | −$66.05M | Paused See the note under the price. |
| FY23 (Sep 30, 2023) | $0.00 | −$58.98M | Paused See the note under the price. |
| FY24 (Sep 30, 2024) | $0.00 | −$75.37M | −$4.06 |
| FY25 (Sep 30, 2025) | $1.41M | −$62.42M | −$1.79 |
Margins
- Gross 195.6%
- Operating 4,781.8%
- Net 5,253.5%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$56.15MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$56.15MLast 12 months
- Capital spending$0.00Last 12 months
- 4,826.5%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $65.83MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $13.77MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$18.43MAs of Jun 30, 2026
- Net debt$4.66MAs of Jun 30, 2026
- 0.81As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- −288.0%Last 12 months
Over the last 12 months, Outlook Therapeutics’s net loss was 288.0% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Outlook Therapeutics Inc
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD, expected in the first half of calendar 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, is being evaluated in an ongoing non-inferiority study for the treatment of wet AMD, and if successful, the data may be sufficient for Outlook to resubmit a BLA to the FDA in the United States. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New Jersey, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
OTLK news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
OTLK stock FAQ
What is OTLK stock’s price today?
Outlook Therapeutics (OTLK) traded at $0.44 at the close on , unchanged from the previous close of $0.44. Over the past 52 weeks it has traded between $0.16 and $2.54.
If you invested $1,000 in OTLK 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in OTLK on would be worth about $1 at the close on , a total return of −99.9%. The same $1,000 would be worth $10 if invested five years ago and $370 if invested one year ago. Past performance doesn’t predict future returns.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market capitalization is about $52.7 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $0.44 (how market cap works). Outlook Therapeutics reported 120.86M shares outstanding at the end of its latest quarter ().
What is OTLK’s P/E ratio?
OTLK’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.77).
What are OTLK’s earnings per share?
OTLK’s diluted earnings per share were −$0.77 over the four quarters to , compared with −$0.57 in the twelve months before. The latest quarter (Q3 FY26) brought −$0.15 per share, against −$0.55 a year earlier (how EPS works).
Does OTLK pay a dividend?
Outlook Therapeutics hasn’t paid a dividend in the last twelve months.
What is OTLK’s 52-week high and low?
Over the past 52 weeks OTLK has traded as low as $0.16 and as high as $2.54. At $0.44 at the close on , it is 82.8% below that high and 170.9% above the low.
What is OTLK’s all-time high?
OTLK’s highest closing price was $867.20 on , adjusted for stock splits. At $0.44 at the close on , it is 99.9% below that record.
Has OTLK stock ever split?
Yes, twice: 1-for-8 on ; 1-for-20 on .
How has OTLK stock performed?
Including dividends and measured to the close on , OTLK has returned −72.4% so far this year and −63.0% over the past year, and −99.0% over five years (−59.8% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Outlook Therapeutics in?
Outlook Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in New Jersey, USA.
What exchange does OTLK trade on?
Outlook Therapeutics trades on the Nasdaq under the ticker symbol OTLK. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.